Assessing the role of low volume disease in endometrial cancer

Bogani, Giorgio; Palaia, Innocenza; Perniola, Giorgia; Fracassi, Alice; Cuccu, Ilaria; D’Augè, Tullio Golia; Casorelli, Assunta; Santangelo, Giusi; Fischetti, Margherita; Muzii, Ludovico; Panici, Pierluigi Benedetti; Donato, Violante Di

doi:10.1016/j.ejogrb.2022.05.014

Cited by 7 publications

(5 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is a growing unmet need to identify the most appropriate adjuvant strategy in EC patients, especially for those with positive nodes and low-volume disease [58,59]. Several prospective study are ongoing to test various adjuvant strategies in those patients [60].…”

Section: Ongoing Trialsmentioning

confidence: 99%

Role of Genomic and Molecular Biology in the Modulation of the Treatment of Endometrial Cancer: Narrative Review and Perspectives

et al. 2023

Self Cite

View full text Add to dashboard Cite

Endometrial cancer (EC) is one of the most common gynecological malignancies in Western countries. Traditionally, loco-reginal dissemination and histological characteristics are the main prognostic factors. Nowadays, molecular and genomic profiling showed exciting results in terms of prognostication. According to the data provided by The Cancer Genome Atlas and other studies, molecular and genomic profiling might be useful in identifying patients al low, intermediate, and high risk of recurrence. However, data regarding the therapeutic value are scant. Several prospective studies are ongoing to identify the most appropriate adjuvant strategy in EC patients, especially for those with positive nodes and low volume disease. The molecular classification has offered the possibility to improve the risk stratification and management of EC. The aim of this review is to focus on the evolution of molecular classification in EC and its impact on the research approach and on clinical management. Molecular and genomic profiling might be useful to tailor the most appropriate adjuvant strategies in apparent early-stage EC.

show abstract

Section: Ongoing Trialsmentioning

confidence: 99%

Role of Genomic and Molecular Biology in the Modulation of the Treatment of Endometrial Cancer: Narrative Review and Perspectives

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

“…Even though the rate of low-volume disease may change depending on the technique used for SLN ultrastaging, 27 it is indisputable that any ultrastaging method will lead to the detection of patients bearing low-volume disease in SLN in a high number. Defining the best adjuvant management for these patients is a clinical need when implementing SLN biopsy as an effective tool of lymph node evaluation in EC.…”

Section: Discussionmentioning

confidence: 99%

Accuracy and Survival Outcomes after National Implementation of Sentinel Lymph Node Biopsy in Early Stage Endometrial Cancer

Cabrera,

Gómez-Hidalgo,

García-Pineda

et al. 2023

Ann Surg Oncol

View full text Add to dashboard Cite

Background Sentinel lymph node (SLN) biopsy has recently been accepted to evaluate nodal status in endometrial cancer at early stage, which is key to tailoring adjuvant treatments. Our aim was to evaluate the national implementation of SLN biopsy in terms of accuracy to detect nodal disease in a clinical setting and oncologic outcomes according to the volume of nodal disease. Patients and Methods A total of 29 Spanish centers participated in this retrospective, multicenter registry including patients with endometrial adenocarcinoma at preoperative early stage who had undergone SLN biopsy between 2015 and 2021. Each center collected data regarding demographic, clinical, histologic, therapeutic, and survival characteristics. Results A total of 892 patients were enrolled. After the surgery, 12.9% were suprastaged to FIGO 2009 stages III–IV and 108 patients (12.1%) had nodal involvement: 54.6% macrometastasis, 22.2% micrometastases, and 23.1% isolated tumor cells (ITC). Sensitivity of SLN biopsy was 93.7% and false negative rate was 6.2%. After a median follow up of 1.81 years, overall surivial and disease-free survival were significantly lower in patients who had macrometastases when compared with patients with negative nodes, micrometastases or ITC. Conclusions In our nationwide cohort we obtained high sensitivity of SLN biopsy to detect nodal disease. The oncologic outcomes of patients with negative nodes and low-volume disease were similar after tailoring adjuvant treatments. In total, 22% of patients with macrometastasis and 50% of patients with micrometastasis were at low risk of nodal metastasis according to their preoperative risk factors, revealing the importance of SLN biopsy in the surgical management of patients with early stage EC.

show abstract

“…Although the delivery of nanoparticles to deep tissue is effective for certain primary tumors, targeting the vascular system presents a more appealing approach for addressing micrometastases [ 100 , 101 , 102 , 103 ]. These smaller, widespread metastatic formations pose a significant challenge for molecular or nanoscale therapeutic agents due to biological hurdles such as their diminutive size and extensive dispersion to various organs, making them nearly impervious to conventional treatments [ 104 , 105 , 106 , 107 , 108 ]. To overcome these obstacles in reaching micrometastatic sites, Peiris et al [ 52 ] have developed an innovative method that integrates vascular targeting techniques with the advanced targeting properties of gold nanoparticles, offering a new avenue for effectively addressing micrometastatic breast cancer.…”

Section: Drug Delivery Systems and Recognition In Angiogenesis And Lu...mentioning

confidence: 99%

Molecular Imaging for Lung Cancer: Exploring Small Molecules, Peptides, and Beyond in Radiolabeled Diagnostics

Ekinci,

Magne,

Alencar

et al. 2024

Pharmaceutics

View full text Add to dashboard Cite

It is evident that radiolabeled drug delivery systems hold great promise in the field of lung cancer management. The combination of therapeutic agents with radiotracers not only allows for precise localization within lung tumors but also enables real-time monitoring of drug distribution. This approach has the potential to enhance targeted therapy and improve patient outcomes. The integration of advanced imaging modalities, such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT), has played a crucial role in the non-invasive tracking of radiolabeled drugs. These techniques provide valuable insights into drug pharmacokinetics, biodistribution, and tumor-targeting efficiency, offering clinicians the ability to personalize treatment regimens. The comprehensive analysis of preclinical and clinical studies presented in this review underscores the progress made in the field. The evidence suggests that radiolabeled drug delivery systems have the potential to revolutionize oncology by offering precise, targeted, and image-guided therapeutic interventions for lung cancer. This innovative approach not only enhances the effectiveness of treatment but also contributes to the development of personalized medicine strategies, tailoring interventions to the specific characteristics of each patient’s cancer. The ongoing research in this area holds promise for further advancements in lung cancer management, potentially leading to improved outcomes and quality of life for patients.

show abstract

Assessing the role of low volume disease in endometrial cancer

Cited by 7 publications

References 35 publications

Role of Genomic and Molecular Biology in the Modulation of the Treatment of Endometrial Cancer: Narrative Review and Perspectives

Role of Genomic and Molecular Biology in the Modulation of the Treatment of Endometrial Cancer: Narrative Review and Perspectives

Accuracy and Survival Outcomes after National Implementation of Sentinel Lymph Node Biopsy in Early Stage Endometrial Cancer

Molecular Imaging for Lung Cancer: Exploring Small Molecules, Peptides, and Beyond in Radiolabeled Diagnostics

Contact Info

Product

Resources

About